Dual-function nanosystem for synergetic cancer chemo-/radiotherapy through ROS-mediated signaling pathways

Biomaterials

Volumn 51, Issue , 2015, Pages 30-42

  He, Lizhen ^a   Lai, Haoqiang ^a   Chen, Tianfeng ^a  

^a JINAN UNIVERSITY   (China)

Author keywords

Apoptosis; Mesoporous silica nanoparticles; Radiotherapy; Targeted nanodrug delivery

Indexed keywords

CELL DEATH; CELL PROLIFERATION; DISEASES; LANTHANUM COMPOUNDS; MAMMALS; MOLECULAR BIOLOGY; NANOPARTICLES; NANOSYSTEMS; RADIOTHERAPY; SILICA; SILICA NANOPARTICLES; TUMORS; X RAYS;

CELL-PENETRATING PEPTIDE; CERVICAL CANCER CELLS; EXPERIMENTAL CONDITIONS; HISTOLOGICAL ANALYSIS; MEDIATED SIGNALING PATHWAYS; MESOPOROUS SILICA NANOPARTICLES; RECEPTOR-MEDIATED ENDOCYTOSIS; TARGETED NANODRUG DELIVERY;

SELENIUM COMPOUNDS;

CASPASE 8; CELL PENETRATING PEPTIDE; DEATH RECEPTOR; KI 67 ANTIGEN; MITOGEN ACTIVATED PROTEIN KINASE; MULTIFUNCTIONAL MESOPOROUS SILICA NANOPARTICLE; NANOPARTICLE; PROTEIN KINASE B; PROTEIN P53; REACTIVE OXYGEN METABOLITE; SELENOCYSTINE; SILICA NANOPARTICLE; TRANSFERRIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CYSTINE; NITROGEN; ORGANOSELENIUM DERIVATIVE; SILICON DIOXIDE; TRANSACTIVATOR PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER RADIOTHERAPY; CANCER SIZE; CELL CYCLE ARREST; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CHEMORADIOTHERAPY; CONTROLLED STUDY; DNA FRAGMENTATION; DOWN REGULATION; DRUG ACCUMULATION; DRUG BINDING; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG DISTRIBUTION; DRUG PENETRATION; DRUG RELEASE; DRUG UPTAKE; ENDOCYTOSIS; FEMALE; HEART; HELA CELL LINE; HUMAN; HUMAN CELL; HYDROGEN BOND; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; KIDNEY; LIVER; LUNG; MALE; MOUSE; MULTIMODALITY CANCER THERAPY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SPLEEN; TREATMENT DURATION; UPREGULATION; UTERINE CERVIX CANCER; ZETA POTENTIAL; ANALOGS AND DERIVATIVES; ANIMAL; CHEMISTRY; DNA DAMAGE; DRUG EFFECTS; DRUG SCREENING; INSTITUTE FOR CANCER RESEARCH MOUSE; INTRACELLULAR SPACE; METABOLISM; NEOPLASMS; NUDE MOUSE; POROSITY; RADIATION RESPONSE; RADIOGRAPHY; SIGNAL TRANSDUCTION; TUMOR CELL LINE; ULTRASTRUCTURE; X RAY; X RAY PHOTOELECTRON SPECTROSCOPY;

MUS MUSCULUS;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CYSTINE; DNA DAMAGE; DRUG DELIVERY SYSTEMS; HUMANS; INTRACELLULAR SPACE; MALE; MICE, INBRED ICR; MICE, NUDE; NANOPARTICLES; NEOPLASMS; NITROGEN; ORGANOSELENIUM COMPOUNDS; PHOTOELECTRON SPECTROSCOPY; POROSITY; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION; SILICON DIOXIDE; TAT GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; TRANSFERRIN; X-RAYS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84924911894     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2015.01.063     Document Type: Article

References (66)

1. Farokhzad O.C., Langer R. Impact of nanotechnology on drug delivery. ACS Nano 2009, 3:16-20.
2. Koley P., Pramanik A. Nanostructures from single amino acid-based molecules:stability, fibrillation, encapsulation, and fabrication of silver nanoparticles. Adv Funct Mater 2011, 21:4126-4136.
3. Minelli C., LS B., SM M. Engineering nanocomposite materials for cancer therapy. Small 2010, 6:2336-2357.
4. Peer D., Karp J.M., Hong S., Farokhzad O.C., Margalit R., Langer R. Nanocarriers asan emerging platform for cancer therapy. Nat Nanotechnol 2007, 2:751-760.
5. Barreto J.A., O'Malley W., Kubeil M., Graham B., Stephan H., Spiccia L. Nanomaterials: applications in cancer imaging and therapy. Adv Mater 2011, 23:H18-H40.
6. Chow E.K., Ho D. Cancer nanomedicine: from drug delivery to imaging. Sci Transl Med 2013, 5. 216rv4.
7. El-Gogary R.I., Rubio N., Wang J.T., Al-Jamal W.T., Bourgognon M., Kafa H., et al. Polyethylene glycol conjugated polymeric nanocapsules for targeted delivery of quercetin to folate-expressing cancer cells invitro and invivo. ACS Nano 2014, 8:1384-1401.
8. Zhang Q., Jiang Q., Li N., Dai L., Liu Q., Song L., et al. DNA origami as an invivo drug delivery vehicle for cancer therapy. ACS Nano 2014, 8:6633-6643.
9. Barenholz Y. Doxil(R)-the first FDA-approved nano-drug: lessons learned. JControl Release 2012, 160:117-134.
10. Miele E., Spinelli G.P., Miele E., Tomao F., Tomao S. Albumin-bound formulation of paclitaxel (Abraxane ABI-007) in the treatment of breast cancer. Int J Nanomedicine 2009, 4:99-105.
11. Ashley C.E., Carnes E.C., Phillips G.K., Padilla D., Durfee P.N., Brown P.A., et al. The targeted delivery of multicomponent cargos to cancer cells by nanoporous particle-supported lipid bilayers. Nat Mater 2011, 10:389-397.
12. Nel A.E., Madler L., Velegol D., Xia T., Hoek E.M., Somasundaran P., et al. Understanding biophysicochemical interactions at the nano-bio interface. Nat Mater 2009, 8:543-557.
13. Ferrari M. Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer 2005, 5:161-171.
14. He Q., Shi J. MSN anti-cancer nanomedicines: chemotherapy enhancement, overcoming of drug resistance, and metastasis inhibition. Adv Mater 2014, 26:391-411.
15. Chen Y., Chen H., Shi J. Invivo bio-safety evaluations and diagnostic/therapeutic applications of chemically designed mesoporous silica nanoparticles. Adv Mater 2013, 25:3144-3176.
16. Shi J., Votruba A.R., Farokhzad O.C., Langer R. Nanotechnology in drug delivery and tissue engineering: from discovery to applications. Nano Lett 2010, 10:3223-3230.
17. Pan L., He Q., Liu J., Chen Y., Ma M., Zhang L., et al. Nuclear-targeted drug delivery of TAT peptide-conjugated monodisperse mesoporous silica nanoparticles. JAm Chem Soc 2012, 134:5722-5725.
18. 2+-dependent intracellular drug delivery system developed with "raspberry-type" particles-on-a-particle comprising mesoporous silica core and alpha-synuclein-coated gold nanoparticles. ACS Nano 2014, 8:8887-8895.
19. Argyo C., Weiss V., Bräuchle C., Bein T. Multifunctional mesoporous silica nanoparticles as a universal platform for drug delivery. Chem Mater 2014, 26:435-451.
20. Fan W., Shen B., Bu W., Chen F., Zhao K., Zhang S., et al. Rattle-structured multifunctional nanotheranostics for synergetic chemo-/radiotherapy and simultaneous magnetic/luminescent dual-mode imaging. JAm Chem Soc 2013, 135:6494-6503.
21. Yanes R.E., Tarn D., Hwang A.A., Ferris D.P., Sherman S.P., Thomas C.R., et al. Involvement of lysosomal exocytosis in the excretion of mesoporous silica nanoparticles and enhancement of the drug delivery effect by exocytosis inhibition. Small 2013, 9:697-704.
22. Xiao D., Jia H.Z., Zhang J., Liu C.W., Zhuo R.X., Zhang X.Z. Adual-responsive mesoporous silica nanoparticle for tumor-triggered targeting drug delivery. Small 2014, 10:591-598.
23. He Q., Zhang Z., Gao F., Li Y., Shi J. Invivo biodistribution and urinary excretion of mesoporous silica nanoparticles: effects of particle size and PEGylation. Small 2011, 7:271-280.
24. He Q., Zhang Z., Gao Y., Shi J., Li Y. Intracellular localization and cytotoxicity of spherical mesoporous silica nano- and microparticles. Small 2009, 5:2722-2729.
25. Lin Y.S., Haynes C.L. Impacts of mesoporous silica nanoparticle size, pore ordering, and pore integrity on hemolytic activity. JAm Chem Soc 2010, 132:4834-4842.
26. Ferrari M. Nanogeometry: beyond drug delivery. Nat Nanotechnol 2008, 3:131-132.
27. Muhammad F., Guo M., Qi W., Sun F., Wang A., Guo Y., et al. pH-Triggered controlled drug release from mesoporous silica nanoparticles via intracelluar dissolution of ZnO nanolids. JAm Chem Soc 2011, 133:8778-8781.
28. Thornton P.D., Heise A. Highly specific dual enzyme-mediated payload release from peptide-coated silica particles. JAm Chem Soc 2010, 132:2024-2028.
29. Zhao Y., Trewyn B.G., Slowing, Lin V.S. Mesoporous silica nanoparticle-based double drug delivery system for glucose-responsive controlled release of insulin and cyclic AMP. JAm Chem Soc 2009, 131:8398-8400.
30. Singh N., Karambelkar A., Gu L., Lin K., Miller J.S., Chen C.S., et al. Bioresponsive mesoporous silica nanoparticles for triggered drug release. JAm Chem Soc 2011, 133:19582-19585.
31. He L., Huang Y., Zhu H., Pang G., Zheng W., Wong Y.-S., et al. Cancer-targeted monodisperse mesoporous silica nanoparticles as carrier of ruthenium polypyridyl complexes to enhance theranostic effects. Adv Funct Mater 2014, 24. 2737-2915.
32. He L., Chen T., You Y., Hu H., Zheng W., Kwong W.L., et al. Acancer-targeted nanosystem for delivery of gold(III) complexes: enhanced selectivity and apoptosis-inducing efficacy of a Gold(III) porphyrin complex. Angew Chem Int Ed Engl 2014, 53:12532-12536.
33. Hoshikawa H., Indo K., Mori T., Mori N. Enhancement of the radiation effects by D-allose in head and neck cancer cells. Cancer Lett 2011, 306:60-66.
34. Afshar G., Jelluma N., Yang X., Basila D., Arvold N.D., Karlsson A., et al. Radiation-induced caspase-8 mediates p53-independent apoptosis in glioma cells. Cancer Res 2006, 66:4223-4232.
35. Takeshima T., Chamoto K., Wakita D., Ohkuri T., Togashi Y., Shirato H., et al. Local radiation therapy inhibits tumor growth through the generation of tumor-specific CTL: its potentiation by combination with Th1 cell therapy. Cancer Res 2010, 70:2697-2706.
36. Lord C.J., Ashworth A. The DNA damage response and cancer therapy. Nature 2012, 481:287-294.
37. Nakae T., Uto Y., Tanaka M., Shibata H., Nakata E., Tominaga M., et al. Design, synthesis, and radiosensitizing activities of sugar-hybrid hypoxic cell radiosensitizers. Bioorg Med Chem 2008, 16:675-682.
38. Beskow C., Skikuniene J., Holgersson A., Nilsson B., Lewensohn R., Kanter L., et al. Radioresistant cervical cancer shows upregulation of the NHEJ proteins DNA-PKcs, Ku70 and Ku86. Br J Cancer 2009, 101:816-821.
39. Wang M., Morsbach F., Sander D., Gheorghiu L., Nanda A., Benes C., et al. EGF receptor inhibition radiosensitizes NSCLC cells by inducing senescence in cells sustaining DNA double-strand breaks. Cancer Res 2011, 71:6261-6269.
40. Xiao Q., Zheng X., Bu W., Ge W., Zhang S., Chen F., et al. Acore/satellite multifunctional nanotheranostic for invivo imaging and tumor eradication by radiation/photothermal synergistic therapy. JAm Chem Soc 2013, 135:13041-13048.
41. Starkewolf Z.B., Miyachi L., Wong J., Guo T. X-ray triggered release of doxorubicin from nanoparticle drug carriers for cancer therapy. Chem Commun 2013, 49:2545-2547.
42. Horie M., Kato H., Fujita K., Endoh S., Iwahashi H. Invitro evaluation of cellular response induced by manufactured nanoparticles. Chem Res Toxicol 2012, 25:605-619.
43. Rabolli V., Thomassen L.C., Uwambayinema F., Martens J.A., Lison D. The cytotoxic activity of amorphous silica nanoparticles is mainly influenced by surface area and not by aggregation. Toxicol Lett 2011, 206:197-203.
44. Card J.W., Magnuson B.A. Amethod to assess the quality of studies that examine the toxicity of engineered nanomaterials. Int J Toxicol 2010, 29:402-410.
45. Liu W., Li X.L., Wong Y.S., Zheng W.J., Zhang Y.B., Cao W.Q., et al. Selenium nanoparticles as a carrier of 5-Fluorouracil to achieve anticancer synergism. Acs Nano 2012, 6:6578-6591.
46. Prokopczyk B., Rosa J.G., Desai D., Amin S., Sohn O.S., Fiala E.S., et al. Chemoprevention of lung tumorigenesis induced by a mixture of benzo(a)pyrene and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone by the organoselenium compound 1,4-phenylenebis(methylene)selenocyanate. Cancer Lett 2000, 161:35-46.
47. Puspitasari I.M., Abdulah R., Yamazaki C., Kameo S., Nakano T., Koyama H. Updates on clinical studies of selenium supplementation in radiotherapy. Radiat Oncol 2014, 9:125.
48. Buentzel J., Micke O., Kisters K., Bruns F., Glatzel M., Schoenekaes K., et al. Selenium substitution during radiotherapy of solid tumours-laboratory data from two observation studies in gynaecological and head and neck cancer patients. Anticancer Res 2010, 30:1783-1786.
49. Ma N., Xu H., An L., Li J., Sun Z., Zhang X. Radiation-sensitive diselenide block co-polymer micellar aggregates: toward the combination of radiotherapy and chemotherapy. Langmuir 2011, 27:5874-5878.
50. Zeng Y.C., Xue M., Chi F., Xu Z.G., Fan G.L., Fan Y.C., et al. Serum levels of selenium in patients with brain metastases from non-small cell lung cancer before and after radiotherapy. Cancer Radiother 2012, 16:179-182.
51. Chen T., Wong Y.S. Selenocystine induces apoptosis of A375 human melanoma cells by activating ROS-mediated mitochondrial pathway and p53 phosphorylation. Cell Mol Life Sci 2008, 65:2763-2775.
52. Chen T., Wong Y.S. Selenocystine induces S-phase arrest and apoptosis in human breast adenocarcinoma MCF-7 cells by modulating ERK and Akt phosphorylation. JAgric Food Chem 2008, 56:10574-10581.
53. Chen T., Wong Y.S. Selenocystine induces caspase-independent apoptosis in MCF-7 human breast carcinoma cells with involvement of p53 phosphorylation and reactive oxygen species generation. Int J Biochem Cell Biol 2009, 41:666-676.
54. Chen T., Wong Y.S. Selenocystine induces reactive oxygen species-mediated apoptosis in human cancer cells. Biomed Pharmacother 2009, 63:105-113.
55. Fan C., Jiang J., Yin X., Wong K.-H., Zheng W., Chen T. Purification of selenium-containing allophycocyanin from selenium-enriched spirulina platensis and its hepatoprotective effect against t-BOOH-induced apoptosis. Food Chem 2012, 134:253-261.
56. Li H., Sun H., Qian Z.M. The role of the transferrin-transferrin-receptor system in drug delivery and targeting. Trends Pharmacol Sci 2002, 23:206-209.
57. Kondo E., Saito K., Tashiro Y., Kamide K., Uno S., Furuya T., et al. Tumour lineage-homing cell-penetrating peptides as anticancer molecular delivery systems. Nat Commun 2012, 3:951.
58. Sinha R., Ei-Bayoumy K. Apoptosis is a critical cellular event in cancer chemoprevention and chemotherapy by selenium compounds. Curr Cancer Tar 2004, 4:13-28.
59. Azzam E.I., de Toledo S.M., Little J.B. Stress signaling from irradiated to non-irradiated cells. Curr Cancer Drug Targets 2004, 4:53-64.
60. Chen T., Wong Y.S., Zheng W., Bai Y., Huang L. Selenium nanoparticles fabricated in Undaria pinnatifida polysaccharide solutions induce mitochondria-mediated apoptosis in A375 human melanoma cells. Colloids Surf B Biointerfaces 2008, 67:26-31.
61. Pelicano H., Carney D., Huang P. ROS stress in cancer cells and therapeutic implications. Drug Resist Update 2004, 7:97-110.
62. Kobayashi K., Usami N., Porcel E., Lacombe S., Le Sech C. Enhancement of radiation effect by heavy elements. Mutat Res 2010, 704:123-131.
63. Nagy V.M., Buiga R., Brie I., Todor N., Tudoran O., Ordeanu C., et al. Expression of VEGF, VEGFR, EGFR, COX-2 and MVD in cervical carcinoma, in relation with the response to radio-chemotherapy. Rom J Morphol Embryol 2011, 52:53-59.
64. Nguyen G.H., Murph M.M., Chang J.Y. Cancer stem cell radioresistance and enrichment: where frontline radiation therapy may fail in lung and esophageal cancers. Cancers 2011, 3:1232-1252.
65. Brem R., Hall J. XRCC1 is required for DNA single-strand break repair in human cells. Nucleic Acids Res 2005, 33:2512-2520.
66. Iftner T., Elbel M., Schopp B., Hiller T., Loizou J.I., Caldecott K.W., et al. Interference of papillomavirus E6 protein with single-strand break repair by interaction with XRCC1. EMBO J 2002, 21:4741-4748.